Pacylex Pharmaceuticals Inc.

Calgary, A0 · Biotech · Private

Small molecule and antibody-drug conjugate (ADC) payload therapies for cancer

Claim this profile

Follows are private to you and power your alerts

Updated · pacylex.com

Sector
Biotech
Headquarters
Calgary, A0
Latest Form D
$75K, Apr 2024
Total capital
$7.3M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$7.3M
2 Form D · last Apr 2024
31 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
3
7 pending · first 2021
Rank in peer group#339 of 1449

Capital timeline

2021202220232024FEDERAL ↑EQUITY ↓Cumulative $7.3M1st Form D$7.2M2nd Form D$75K
2021202220232024FEDERAL ↑EQUITY ↓Cumulative $7.3M1st Form D$7.2M2nd Form D$75K

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$75K
  • Private capital raisedForm D · SEC · 1st filing$7.2M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#339 · top 23%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Luc G. BerthiaumeResearcherDirectorLinked by 3 patents
  • Ajit G. GillDirectorNamed in SEC Form D filings
  • Cindy JacobsDirectorNamed in SEC Form D filings
  • John G. MackeyDirectorNamed in SEC Form D filings
  • Mark HusonDirectorNamed in SEC Form D filings
  • Michael WeickertExecutive Officer, DirectorNamed in SEC Form D filings
Show all 8 people
  • Nola G. MastersonDirectorNamed in SEC Form D filings
  • Ryan G. HeitExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 3 granted of 10
  • GrantedSynthetic Lethality And The Treatment Of CancerUSPTOUS 12,343,341
  • PendingSynthetic Lethality And The Treatment Of CancerUSPTOApplication 19056076
  • PendingOral PCLX-001 In The Treatment Of Human CancerUSPTOApplication 18841472
Show all 10 patent records
  • Synthetic Lethality And The Treatment Of CancerJul 1, 2025 · US 12,343,341Granted
  • Synthetic Lethality And The Treatment Of CancerJun 5, 2025 · Application 19056076Pending
  • Oral PCLX-001 In The Treatment Of Human CancerMay 22, 2025 · Application 18841472Pending
  • Use Of N-myristoyl Transferase (nmt) Inhibitors In The Treatment Of Cancer, Autoimmune Disorders, And Inflammatory DisordersOct 24, 2024 · Application 18031772Pending
  • Synthetic Lethality And The Treatment Of CancerNov 23, 2023 · Application 18126275Pending
  • Epigenetic Silencing Of NMT2Oct 17, 2023 · US 11,788,145Granted
  • Synthetic Lethality And The Treatment Of CancerOct 5, 2021 · US 11,135,218Granted
  • Synthetic Lethality And The Treatment Of CancerJan 10, 2019 · Application 15943068Pending
  • Synthetic Lethality And The Treatment Of CancerOct 1, 2015 · Application 14438594Pending
  • Methods And Compositions For Diagnosis And Prognosis In Breast CancerAug 6, 2015 · Application 14418939Pending
  • Halodine LLCSimilar federal contract value in Biotech · null in contracts
  • Osmol TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Gennao BioSimilar federal contract value in Biotech · null in contracts
  • Angstrom Bio, Inc.Similar federal contract value in Biotech · null in contracts
  • BIOPICO SYSTEMS Inc.Similar federal contract value in Biotech · null in contracts
  • Aliada TherapeuticsSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .